Lv5
1100 积分 2024-05-20 加入
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial
2小时前
待确认
The Interpretation of Interaction in Contingency Tables
17天前
已完结
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
1个月前
已完结
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score
1个月前
已完结
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
1个月前
已完结
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
1个月前
已完结
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
1个月前
已完结
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
1个月前
已完结
References
1个月前
已完结
Delays in publishing systematic review registrations in PROSPERO are hindering transparency and may lead to research waste
1个月前
已完结
皖公网安备34019202002308
